Abstract CT250: A phase 1b / 2 study of JK06, a 5T4-targeted antibody drug conjugate, in patients with unresectable locally advanced or metastatic cancerOmar Saavedra, Nuria Kotecki, V. Boni et al.|Cancer Research|2026Cited by 0